The revenue of Danish allergy group ALK has increased to approximately DKK 3 billion (USD 460 million), however, the bottom line and EBIT remain negative.Despite red numbers, ALK increase investments in the coming year. "ALK is a growth case, and it also entails short-term costs," says the CEO.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.